Livalo Acute Myocardial Infarction Study (LAMIS)

JW Pharmaceutical

Status: Completed

Conditions: Acute Myocardial Infarction

Study type: Observational

Funder types: Industry

Identifiers

NCT01265706

PTV_LAMIS II

Details and patient eligibility

About

This study is performed to observe the incidence of major cardiovascular events in Korean patients with AMI after giving pitavastatin 2mg and 4mg longer than 1 year.

Enrollment: 1,000 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with STEMI, NSTEMI

• Patients satisfying at least one of the followings

  1. Patients with LDL-C ≥ 130 mg/dL
  2. Patients with LDL-C ≥ 100 mg/dL who are regarded as required cholesterol lowering therapy by the investigator
  3. Patients taking statin are required continuous cholesterol lowering therapy

• Patients satisfying at least two of the followings

  1. The change of Ischemic ECG
  2. CK, CK-MB, Troponin-I increased more than two times
  3. The symptom of ACS

Exclusion criteria

1. Patients with in-stent restenosis after PCI or coronary artery bypass
2. Patients with cardiogenic shock
3. Patients with severe heart failure (Left ventricular ejection fraction is less than 30%)
4. Patients who are taking cyclosporine
5. Patients who experienced hypersensitivity to pitavastatin
6. Patients under dialysis treatment
7. Patients who are participating other clinical trials
8. Patients who can not stop taking concomitant drugs
9. Pregnant or lactating women or suspected pregnancy
10. Patients who are regarded as ineligible for this study by the investigator